Galderma Group AG
🇨🇭Switzerland
Clinical Trials
294
Active:28
Completed:249
Trial Phases
5 Phases
Phase 1:23
Phase 2:32
Phase 3:65
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (271 trials with phase data)• Click on a phase to view related trials
Not Applicable
79 (29.2%)Phase 4
72 (26.6%)Phase 3
65 (24.0%)Phase 2
32 (11.8%)Phase 1
23 (8.5%)A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
Not Applicable
Not yet recruiting
- Conditions
- Skin Quality Improvement
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 171
- Registration Number
- NCT07047638
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
Not Applicable
Not yet recruiting
- Conditions
- Systemic Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 162
- Registration Number
- NCT07047690
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Not yet recruiting
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1000
- Registration Number
- NCT06988605
- Locations
- 🇺🇸
Galderma Investigational Site 7061, Castle Rock, Colorado, United States
🇺🇸Galderma Investigational Site 7059, Fairfield, Connecticut, United States
🇺🇸Galderma Investigational Site 7063, Cutler Bay, Florida, United States
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Not yet recruiting
- Conditions
- Prurigo Nodularis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 600
- Registration Number
- NCT06988618
- Locations
- 🇺🇸
Galderma Investigational Site # 8893, Birmingham, Alabama, United States
🇺🇸Galderma Investigational Site # 7077, Phoenix, Arizona, United States
🇺🇸Galderma Investigational Site # 7060, Phoenix, Arizona, United States
Evaluate the Effectiveness and Safety of Restylane Volyme in the Treatment of Temple Hollowing
Not Applicable
Recruiting
- Conditions
- Temple Hollowing
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 162
- Registration Number
- NCT06665477
- Locations
- 🇨🇳
Galderma Investigational Site #6340, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
No news found